Articles by Michael
Activity
3K followers
-
Michael Derby shared thisCongrats to the Timber team on advancing the lead program to this exit! TMB-001 is an important product and will be in good hands at LEO!Michael Derby shared thisI couldn't think of any better company to take the reins. A major congrats to the Timber team for this enormous accomplishment. Looking forward to working with Leo! https://lnkd.in/efk8BKwn
-
Michael Derby shared thisCongratulations to the entire PaxMedica team on this important accomplishment in bringing suramin one step closer to the U.S. market!Michael Derby shared thisPaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
-
Michael Derby shared thisMichael Derby shared thisTune in to the closing bell today - PaxMedica will be ringing it! A moment of celebration for the years of hard work from an extremely dedicated team! There's a lot more to come! https://lnkd.in/eVhDnEMn
-
Michael Derby shared thisI'm excited to announce the IPO of PaxMedica today! It is a key milestone for the company and a pivotal moment to advance treatments for a number of important neurologic conditions. Congrats to the entire team for making this a success in a challenging market! https://lnkd.in/gExzC-jp
-
Michael Derby shared thisI’m very excited to announce positive results from our company’s recently completed Phase 2 study of the investigational drug, PAX-101, in Autism Spectrum Disorder. It is an early but important milestone for PaxMedica, a company we founded, and towards which our extended team has been working tirelessly over the past two years. We look forward to the continued important work ahead as we strive to bring this much needed therapy to children and their families who are living with ASD.
-
Michael Derby shared thisCastle Creek Pharmaceuticals is proud to support the debra of America's #tagwithella campaign. #wefighteb #castlecreektagsella Visit tagwithella.com to learn more about this campaign and how you can help.
-
Michael Derby liked thisMichael Derby liked thisPleased to license Maxigesic IV in Japan - worlds 3rd largest Pharma Market - more positive progress
-
Michael Derby liked thisMichael Derby liked thisGreat and insightful meeting today in NYC with Mark Cuban to discuss drug pricing and distribution strategies in USA and our partnership with Cost Plus for our latest USA launch
-
Michael Derby liked thisVery honored to have been selected for this!Michael Derby liked thisWe’re incredibly excited - and proud - to share that NatEureka Labs has been selected as one of just 10 companies invited to present at the upcoming Dentech conference, hosted by The ADA Forsyth Institute. Dentech is an invite-only innovation and investment forum that brings together leading voices from research, industry, academia, and venture capital to help accelerate innovation and launch the next generation of companies in oral health. We’re honored to be included among this group and excited for the opportunity to share what we’re building at NatEureka and Cazu. Looking forward to Boston in a couple of weeks! #dentech2026
-
Michael Derby liked thisAnother milestone achieved🎊Michael Derby liked this🚀 TWi Biotechnology Successfully Completes $15M USD Fundraising! We are excited to share a major milestone: TWi Biotechnology has successfully closed a USD 15 Million (NTD 450 Million) million funding round! 🏅 This new capital will be pivotal in driving our lead program, AC-203, through global regulatory activities and commercialization preparations as we position it for market authorization. 🌱 What’s Next for AC-203? With all 81 patients in the global Phase 2/3 pivotal EBShield Study having completed their primary efficacy assessments, we are now swiftly advancing toward our next key milestone: 👉 Topline data readout in Q4 2026. A heartfelt thank you to our investors and partners for their unwavering trust and shared vision in delivering innovative therapies to patients in need. Fundraising completed. Next major milestone ahead! 💡 #EpidermolysisBullosa #RareDisease #TWiB #AC203
-
Michael Derby liked thisMichael Derby liked thisBehind the Scenes of our Global Webinar 🎬 What a journey it has been. Our team spent months preparing and coordinating across time zones, running late-night rehearsals, and working together toward one shared goal of bringing the global EB community together for this 2-hour webinar. We are incredibly grateful to Dr. Johann Bauer and Dr. Amy Paller, two internationally recognized EB experts, for sharing their invaluable clinical experience and perspectives; and to our senior consultant, Dr. Yiumo Michael Chan, for sharing insights shaped by decades of research in EB Simplex; and, of course, our amazing President, Dr. Chen-En Tsai, for hosting. A huge thank you also goes to our amazing production team, who worked with us well past midnight local time to make sure everything ran smoothly behind the scenes. This webinar simply would not have been possible without their professionalism and dedication. Most importantly, we were deeply encouraged by the enthusiasm of EB patients, families, clinicians, researchers, advocates, and industry colleagues from around the world who joined us. A special shout-out to debra of America and DEBRA Australia for helping share the webinar with the EB community. For our team, AC-203 represents years of work toward a potential treatment option for people living with EB Simplex, a condition for which there is currently no approved disease-specific therapy. There is still work ahead, and the data will ultimately speak for itself. But after such a long journey, we believe we are finally nearing the light at the end of the tunnel. AC-203 Phase 2/3 topline results are coming in Q4 2026. Thank you to everyone who has been part of this journey with us. 🧡
-
Michael Derby liked thisHappy to announce that I have joined Helus Pharma as Chief People Officer! #HELP #HelusPharma #HelpingMindsHealMichael Derby liked thisWe are pleased to welcome Regina Dolan Donohue, SPHR, SHRM-SCP as our new Chief People Officer and Suresh Durgam MD to our Scientific Advisory Board. #HELP #HelusPharma
-
Michael Derby liked thisMichael Derby liked thisCongratulations to our 2026 high school interns! These 8 future scientists presented original research on July 31 to mentors, peers and loved ones. Their futures are bright, and we're honored to have hosted them in our prestigious program. Learn more: https://lnkd.in/gswtvjQV
Experience & Education
Other similar profiles
Explore more posts
-
Chase Feiger, M.D.
The latest episode of the Kinara podcast is now live! I sat down with Steven Basta, CEO of Phathom Pharmaceuticals, for a candid conversation on building a focused biopharma company, making disciplined strategic bets, and what it takes to bring genuinely differentiated therapies to patients. Steve brings a clear, operator’s perspective on leadership in biotech. We also get into the realities of launching in today’s environment, aligning science with commercialization, and avoiding the noise that pulls teams away from what actually matters. Watch the trailer below and find the link to the full episode!
1 Comment -
Darin DeWitt
Three sectors haven't needed a Q2 update. Specialty pharma, medtech, and CDMO are running on the same thesis since March, and it's still accelerating. Specialty pharma remains the most consequential story in pharma. GLP-1 alone spans 120-plus assets across 60-plus companies, with an active M&A pipeline pulling acquirers further upstream and direct-to-consumer models accelerating the split between specialty and commodity pharmacy. Medtech has the best investor sentiment in three years. Global VC activity is at a three-year high, large strategics are re-engaging after a divestiture cycle, and the IPO window reopened with Medline's $6.26 billion listing, the largest healthcare IPO of 2025. CDMO demand keeps climbing on the same two drivers: GLP-1 manufacturing capacity expansion and a growing AI-native biotech pipeline that needs outsourced complex biologics and oral drug delivery capability. None of that shows up as pressure to build faster. It shows up as pressure to have the right leadership in place before the window narrows. Pre-IPO CFOs with public markets experience are the scarcest hire on the list. Specialty pharmacy C-suites built for GLP-1 and PBM disruption, and CDMO business development and operations leaders who can scale manufacturing capacity, round out where the demand is concentrated. While services works through a correction, these three sectors are still in growth mode. The leadership gap is the constraint, not the capital.
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content